Effects of Metformin on Endometrial Cancer Cell Growth in Vivo: A Preoperative Prospective Trial
Effects of Metformin on Endometrial Cancer Cell Growth in Vivo: A Preoperative Prospective Trial
复制标题
DOI：
10.1002/cncr.28853
复制
发表时间：
2014-10-01
期刊：
影响因子：
6.2
通讯作者：
Shozu, Makio
中科院分区：
文献类型：
--
作者：
Mitsuhashi, Akira;Kiyokawa, Takako;Shozu, Makio
BACKGROUND: Metformin, an antidiabetic drug, decreases the incidence of various cancers in diabetic patients. Metformin-induced inhibition of cancer cell proliferation has been confirmed in vitro but not in humans. Because endometrial cancer is associated with insulin resistance, the authors investigated whether a diabetes-therapeutic metformin dose inhibits cancer cell growth in patients with endometrial cancer. METHODS: A dose of metaformin was administered (1500-2250 mg/day) to 31 patients with endometrial cancer preoperatively for 4 to 6 weeks. Cell proliferation was assessed in patient tissues using immunohistochemical and Western blot analyses and DNA synthesis was measured in serum using a thymidine uptake assay. All statistical tests were 2-sided. P values of
